Evidence for weak protein binding of commercial extracellular gadolinium contrast agents

Magnetic Resonance in Medicine

Volumn 63, Issue 3, 2010, Pages 609-616

  Wang, Yan ^a   Spiller, Marga ^b   Caravan, Peter ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Gadodiamide; Gadolinium; Gd DTPA; Protein binding; Relaxometry

Indexed keywords

DAIRIES; ENZYMES; GADOLINIUM;

CHICKEN EGG WHITE LYSOZYME; GADODIAMIDE; GADOLINIUM CONTRAST AGENTS; GD-DTPA; HUMAN SERUM ALBUMINS; NUCLEAR MAGNETIC RELAXATION DISPERSION; PROTEIN BINDING; RELAXOMETRY;

BIOCHEMISTRY;

GADODIAMIDE; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE; HUMAN SERUM ALBUMIN; LYSOZYME; MILK PROTEIN;

ARTICLE; BINDING AFFINITY; DRUG DETERMINATION; DRUG PROTEIN BINDING; VISCOSITY;

EID: 77649105778     PISSN: 07403194     EISSN: 15222594     Source Type: Journal    
DOI: 10.1002/mrm.22214     Document Type: Article

References (36)

1. Caravan P, Lauffer RB. Contrast agents: basic principles. In: Edelman RR, Hesselink JR, Zlatkin MB, Crues JV, editors. Clinical magnetic resonance imaging. 3rd ed. Volume 1. Philadelphia: Saunders; 2005. p 357-375.
2. Laurent S, Elst LV, Muller RN. Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agents. Contrast Media Mol Imaging 2006;1:128-137.
3. Normann PT, Hals PA. In vivo stability and excretion of gadodiamide (GdDTPA-BMA), a hydrophilic gadolinium complex used as a contrast enhancing agent for magnetic resonance imaging. Eur J Drug Metab Pharmacokinet 1995;20:307-313.
4. Landis CS, Li X, Telang FW, Coderre JA, Micca PL, Rooney WD, Latour LL, Vetek G, Palyka I, Springer CS Jr. Determination of the MRI contrast agent concentration time course in vivo following bolus injection: effect of equilibrium transcytolemmal water exchange. Magn Reson Med 2000;44:563-574.
5. Li X, Rooney WD, Springer CS Jr. A unified magnetic resonance imaging pharmacokinetic theory: intravascular and extracellular contrast reagents. Magn Reson Med 2005;54:1351-1359.
6. Rosen BR, Belliveau JW, Vevea JM, Brady TJ. Perfusion imaging with NMR contrast agents. Magn Reson Med 1990;14:249-265.
7. Tofts PS. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging 1997;7:91-101.
8. Eldredge HB, Spiller M, Chasse JM, Greenwood MT, Caravan P. Species dependence on plasma protein binding and relaxivity of the gadolinium-based MRI contrast agent MS-325. Invest Radiol 2006;41: 229-243.
9. Caravan P. Strategies for increasing the sensitivity of gadolinium based MRI contrast agents. Chem Soc Rev 2006;35:512-523.
10. Grobner T, Prischl FC. Gadolinium and nephrogenic systemic fibrosis. Kidney Int 2007;72:260-264.
11. Broome DR. Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting. Eur J Radiol 2008;66:230-234.
12. Thomsen HS, Marckmann P. Extracellular Gd-CA: differences in prevalence of NSF. Eur J Radiol 2008;66:180-183.
13. Port M, Idee JM, Medina C, Robic C, Sabatou M, Corot C. Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review. Biometals 2008;21:469-480.
14. Idee JM, Port M, Medina C, Lancelot E, Fayoux E, Ballet S, Corot C. Possible involvement of gadolinium chelates in the pathophysiology of nephrogenic systemic fibrosis: a critical review. Toxicology 2008; 248:77-88.
15. Giesel FL, von Tengg-Kobligk H, Wilkinson ID, Siegler P, von der Lieth CW, Frank M, Lodemann KP, Essig M. Influence of human serum albumin on longitudinal and transverse relaxation rates (r1 and r2) of magnetic resonance contrast agents. Invest Radiol 2006;41: 222-228.
16. Pickup S, Wood AK, Kundel HL. Gadodiamide T1 relaxivity in brain tissue in vivo is lower than in saline. Magn Reson Med 2005;53:35-40.
17. Stanisz GJ, Henkelman RM. Gd-DTPA relaxivity depends on macromolecular content. Magn Reson Med 2000;44:665-667.
18. 3+ complexes of interest in magnetic resonance imaging: an integrated and theoretically self-consistent approach. J Am Chem Soc 1996;118:9333-9346.
19. Koenig SH, Brown RD III. Field-cycling relaxometry of protein solutions and tissue: implications for MRI. Prog Nucl Magn Reson Spectrosc 1990;22:487-567.
20. Caravan P, Parigi G, Chasse JM, Cloutier NJ, Ellison JJ, Lauffer RB, Luchinat C, McDermid SA, Spiller M, McMurry TJ. Albumin binding, relaxivity, and water exchange kinetics of the diastereoisomers of MS-325, a gadolinium(III)-based magnetic resonance angiography contrast agent. Inorg Chem 2007;46:6632-6639.
21. Halle B. Protein hydration dynamics in solution: a critical survey. Philos Trans R Soc Lond B Biol Sci 2004;359:1207-1223; discussion 1223-1224, 1323-1328.
22. Modig K, Liepinsh E, Otting G, Halle B. Dynamics of protein and peptide hydration. J Am Chem Soc 2004;126:102-114.
23. Mattea C, Qvist J, Halle B. Dynamics at the protein-water interface from 17O spin relaxation in deeply supercooled solutions. Biophys J 2008;95:2951-2963.
24. Luise A, Falconi M, Desideri A. Molecular dynamics simulation of solvated azurin: correlation between surface solvent accessibility and water residence times. Proteins 2000;39:56-67.
25. Rohrer M, Bauer H, Mintorovitch J, Requardt M, Weinmann HJ. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol 2005;40:715-724.
26. Girard E, Chantalat L, Vicat J, Kahn R. Gd-HPDO3A, a complex to obtain high-phasing-power heavy-atom derivatives for SAD and MAD experiments: results with tetragonal hen egg-white lysozyme. Acta Crystallogr D Biol Crystallogr 2002;58:1-9.
27. Frenzel T, Lengsfeld P, Schirmer H, Hutter J, Weinmann HJ. Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C. Invest Radiol 2008;43:817-828.
28. 3+ ions. Contrast Media Mol Imaging 2006;1:23-29.
29. Buckley DL, Kershaw LE, Stanisz GJ. Cellular-interstitial water exchange and its effect on the determination of contrast agent concentration in vivo: dynamic contrast-enhanced MRI of human internal obturator muscle. Magn Reson Med 2008;60:1011-1019.
30. Landis CS, Li X, Telang FW, Molina PE, Palyka I, Vetek G, Springer CS Jr. Equilibrium transcytolemmal water-exchange kinetics in skeletal muscle in vivo. Magn Reson Med 1999;42:467-478.
31. Wedeking P, Sotak CH, Telser J, Kumar K, Chang CA, Tweedle MF. Quantitative dependence of MR signal intensity on tissue concentration of Gd(HP-DO3A) in the nephrectomized rat. Magn Reson Imaging 1992;10:97-108.
32. Decking UK, Pai VM, Wen H, Balaban RS. Does binding of Gd-DTPA to myocardial tissue contribute to late enhancement in a model of acute myocardial infarction? Magn Reson Med 2003;49:168-171.
33. Caravan P, Farrar CT, Frullano L, Uppal R. Influence of molecular parameters and increasing magnetic field strength on relaxivity of gadolinium- and manganese-based T(1) contrast agents. Contrast Media Mol Imaging 2009;4:89-100.
34. Tombach B, Bremer C, Reimer P, Schaefer RM, Ebert W, Geens V, Heindel W. Pharmacokinetics of 1M gadobutrol in patients with chronic renal failure. Invest Radiol 2000;35:35-40.
35. Joffe P, Thomsen HS, Meusel M. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol 1998;5:491-502.
36. Schuhmann-Giampieri G, Krestin G. Pharmacokinetics of Gd-DTPA in patients with chronic renal failure. Invest Radiol 1991;26:975-979.